Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells

Breast Cancer Research and Treatment

Volumn 80, Issue 2, 2003, Pages 181-191

  Gurel, Volkan ^a,b   Sens, Donald A ^a   Somji, Seema ^a   Garrett, Scott H ^a   Nath, Joginder ^b   Sens, Mary Ann ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Breast cancer; Cadmium resistance; Cell growth; Hs578T; MCF 7; MDA MB 231; Metallothionein; MT 3; T 47D

Indexed keywords

ANTIESTROGEN; CADMIUM; ESTROGEN RECEPTOR; ISOPROTEIN; MESSENGER RNA; METALLOTHIONEIN; METALLOTHIONEIN III; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CELL TYPE; COLONY FORMING CELL; CONTROLLED STUDY; DRUG RESISTANCE; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR STABILITY; MT1E GENE; MT3 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR DENSITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STAINING;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOMERISM; METALLOTHIONEIN; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037998718     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024520801262     Document Type: Article

References (32)

1. Sens MA, Somji S, Garrett SH. Sens DA: Metallothionein isoform 3 (MT-3) overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21-26, 2001
2. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH, Sens DA: Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 108: 413-418, 2000
3. Garrett SH, Sens MA, Shukla E, Nestor S, Somji S, Todd JH, Sens DA: Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 41: 196-202, 1999
4. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards R: Human metallothionein genes: structure of the functional locus at 16q13. Genomics 8: 513-518, 1990
5. Stennard FA, Holloway AF, Hamilton J, West AK: Characterization of six additional human metallothionein genes. Biochim Biophys Acta 1218: 357-365, 1994
6. Palmiter RD, Findley SD, Whitmore TE, Durnam DM: MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci USA 89: 6333-6337, 1992
7. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, Palmiter RD: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33: 7250-7259, 1994
8. Hamer DH: Metallothionein. Ann Rev Biochem 55: 913-951, 1986
9. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M: The growth inhibitory factor that is deficient in Alzheimer's disease is a 68 amino acid metallothionein-like protein. Neuron 7: 337-347, 1991
10. Garrett SH, Sens MA, Todd JH, Somji S, Sens DA: Expression of MT-3 protein in the human kidney. Toxicol Lett 105: 207-214, 1999
11. Dutta R, Sens DA, Somji S, Sens MA, Garrett SH: Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. The Prostate 52: 89-97, 2002
12. Sewell AK, Jensen LT, Erickson JC, Palmiter RD, Winge DR: The bioactivity of metallothionein-3 correlates with its novel β domain sequence rather than metal binding properties. Biochemistry 34: 4740-4747, 1995
13. Tsuji S, Kobayashi H, Uchida Y, Ihara Y, Miyataka T: Molecular cloning of human growth inhibitory factor cDNA and its down-regulation in Alzheimer's disease. EMBO J 11: 4843-4850, 1992
14. 1D receptor genes. Biochem Biophys Res Comm 214: 639-645, 1995
15. Aschner M, Cherian MG, Klaassen CD, Palmiter RD, Erickson JC, Bush AI: Metallothioneins in brain - the role in physiology and pathology. Toxicol Appl Pharmacol 142: 229-242, 1997
16. Friedline JA, Garrett SH, Somji S, Todd JH, Sens DA: Differential expression of the MT-IE gene in estrogen receptor positive and negative human breast cancer cell lines. Am J Pathol 152: 23-28, 1998
17. Garrett SH, Sens MA, Shukla D, Flores L, Somji S, Todd JH, Sens DA: Metallothionein isoform 1 and 2 gene expression in the human prostate: down-regulation of MT-1X in advance prostate cancer. The Prostate 43: 125-135, 2000
18. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
19. Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451-1467, 1998
20. Duffy MJ: Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34: 347-352, 2001
21. Bier B, Douglas-Jones A, Totsch M, Dockhorn-Dworniczak B, Bocker W, Jasani B, Schmid KW: Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant lesions. Breast Cancer Res Treat 30: 213-221, 1994
22. Douglas-Jones AG, Schmid KW, Bier B, Horgan K, Lyons K, Dallimore ND, Moneypenny IJ, Jasani B: Metallothionein expression in duct carcinoma in situ of the breast. Human Pathol 26: 217-222, 1995
23. Fresno M, Wu W, Rodriguez JM, Nadji M: Localization of metallothionein in breast carcinomas: an immunohistochemical study. Virchows Arch A Pathol Anat 423: 215-219, 1993
24. Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, Elston CW, Robertson JF, Blamey RW, Nicholson RA, Schmid KW, Ellis IO: Metallothionein expression in human breast cancer. Br J Cancer 72: 968-972, 1995
25. Haerslev T, Jacobsen K, Nedergaard L, Zedeler K: Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. Path Res Pract 190: 675-681, 1994
26. Oyama T, Takei H, Hikino T, Iino Y, Nakajima T: Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 53: 112-117, 1996
27. Schmid KW, Ellis IO, Gee JMW, Darke BM, Lees WE, Kay J, Cryer A, Stark JM, Hittmair A, Ofner D, Dunser M, Margreiter R, Daxenbichler G, Nicholson RI, Bier B, Bocker W, Jasani B: Presence and possible significance of immunocytochemically demonstratable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat 422: 153-159, 1993
28. Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantis NJ: Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 19: 2133-2140, 1999
29. Palumma P, Eriste E, Njunkova O, Pokras L, Jörnvall H, Sillard R: Brain-specific metallothionein-3 has higher metal-binding capacity than ubiquitous metallothioneins and binds metal noncooperatively. Biochemistry 41: 6158-6163, 2002
30. Hasler DW, Jensen LT, Zerbe O, Winge DR, Vašák M: Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. Biochemistry 39: 14567-14575, 2000
31. Faller P, Hasler DW, Zerbe O, Klauser S, Winge DR, Vašák M: Evidence for a dynamic structure of human neuronal growth inhibitory factor and for major rearrangements of its metal-thiolate clusters. Biochemistry 38: 10158-10167, 1999
32. Öz G, Zangger K, Armitage IM: Three-dimensional structure and dynamics of a brain specific growth inhibitory factor: metallothionein-3. Biochemistry 40: 11433-11441, 2001